Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (74)
Yagiz Aksoy, Angela Chou, Mahiar Mahjoub, Amy Sheen, Loretta Sioson, Mahsa S. Ahadi, Anthony J. Gill & Talia L. Fuchs. (2023) A novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma. Pathology 55:4, pages 449-455.
Crossref
Crossref
Yan Li, Abeer M. Salama, Marina K. Baine, Francis M. Bodd, Michael D. Offin, Natasha Rekhtman, Marjorie G. Zauderer, William D. Travis, Prasad S. Adusumilli & Jennifer L. Sauter. (2023) Reliability of assessing morphologic features with prognostic significance in cytology specimens of epithelioid diffuse pleural mesothelioma and implications for cytopathology reporting. Cancer Cytopathology.
Crossref
Crossref
Mucheng Zhu, Zhenhua Lu, Hao Guo, Xiaoting Gu, Defang Wei & Zhengyi Zhang. (2023) Diagnostic value of combination of biomarkers for malignant pleural mesothelioma: a systematic review and meta-analysis. Frontiers in Oncology 13.
Crossref
Crossref
Karen Walker-Bone, Geza Benke, Ewan MacFarlane, S Klebe, Ken Takahashi, Fraser Brims, Malcolm Ross Sim & Tim R Driscoll. (2023) Incidence and mortality from malignant mesothelioma 1982–2020 and relationship with asbestos exposure: the Australian Mesothelioma Registry. Occupational and Environmental Medicine 80:4, pages 186-191.
Crossref
Crossref
Kyle M. Devins, Lawrence Zukerberg, Jaclyn C. Watkins, Yin Pun Hung & Esther Oliva. (2023) BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma. International Journal of Gynecological Pathology 42:2, pages 159-166.
Crossref
Crossref
Sabah Alaklabi, Arya Roy, Joseph Skitzki & Renuka Iyer. (2023) Immunotherapy in malignant peritoneal mesothelioma (Review). Molecular and Clinical Oncology 18:4.
Crossref
Crossref
Laura Kurth, Jacek M Mazurek & David J Blackley. (2023) Malignant mesothelioma among US Medicare beneficiaries: incidence, prevalence and therapy, 2016–2019. Occupational and Environmental Medicine 80:2, pages 86-92.
Crossref
Crossref
Yunus Güzel, Halil Kömek, Canan Can, İhsan Kaplan, Ferat Kepenek, Senar Ebinç, Mehmet Perver Büyükdeniz, Cihan Gündoğan & Zeynep Oruç. (2023) Comparison of the role of 18F-fluorodeoxyglucose PET/computed tomography and 68Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma. Nuclear Medicine Communications Publish Ahead of Print.
Crossref
Crossref
Cai-Pu Chun, Lin-Xie Song, Hong-Pan Zhang, Dan-Dan Guo, Gui-Xuan Xu, Ya Li, Xin Xin, Jiachen Cao & Feng Li. (2023) Malignant peritoneal mesothelioma. The American Journal of the Medical Sciences 365:1, pages 99-103.
Crossref
Crossref
Lucia Calthorpe, Fernanda Romero-Hernandez, Phoebe Miller, Patricia C. Conroy, Kenzo Hirose, Alex Kim, Kimberly Kirkwood, Eric Nakakura, Carlos Corvera, Ajay V. Maker, Adnan Alseidi & Mohamed Abdelgadir Adam. (2022) Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States. Cancers 15:1, pages 229.
Crossref
Crossref
Fumie Onishi & Nobukazu Fujimoto. 2022. Mesothelioma - Diagnostics, Treatment and Basic Research. Mesothelioma - Diagnostics, Treatment and Basic Research.
Geraldine M. O’Connor & Emyr Y. Bakker. (2022) Patient-Level Omics Data Analysis Identifies Gene-Specific Survival Associations for a PD-1/PD-L1 Network in Pleural Mesothelioma. BioMedInformatics 2:4, pages 580-592.
Crossref
Crossref
Moshe Lapidot, Emanuele Mazzola & Raphael Bueno. (2022) Outcomes of pleurectomy decortication in patients with biphasic mesothelioma. The Journal of Thoracic and Cardiovascular Surgery 164:5, pages 1340-1348.e3.
Crossref
Crossref
Ye Li, Botao Cai, Bing Wang, Yan Lv, Wei He, Xiaoxia Xie & Dailun Hou. (2022) Differentiating malignant pleural mesothelioma and metastatic pleural disease based on a machine learning model with primary CT signs: A multicentre study. Heliyon 8:11, pages e11383.
Crossref
Crossref
Mark D. Danese, Melinda Daumont, Esmond Nwokeji, Michelle Gleeson, John R. Penrod & Deborah Lubeck. (2021) Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results‐Medicare data. Cancer Reports 5:9.
Crossref
Crossref
Dominik Valentin Flury & Gregor J. Kocher. (2022) Epidemiologie, Diagnostik und Therapie des Pleuramesothelioms. InFo Hämatologie + Onkologie 25:7-8, pages 40-61.
Crossref
Crossref
Selma Metintas, Guntulu Ak, Emine Dundar & Muzaffer Metintas. (2022) What has changed in malignant mesothelioma between 1990 and 2019? A time- series analyses in Turkey. International Journal of Clinical Oncology 27:7, pages 1202-1211.
Crossref
Crossref
Moshe Lapidot, Ritu R. Gill, Emanuele Mazzola, Samuel Freyaldenhoven, Scott J. Swanson, Michael T. Jaklitsch, David J. Sugarbaker & Raphael Bueno. (2022) Pleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma. Annals of Surgery 275:6, pages 1212-1220.
Crossref
Crossref
Talia L. Fuchs, Angela Chou, Yagiz Aksoy, Mahiar Mahjoub, Amy Sheen, Loretta Sioson, Mahsa Ahadi & Anthony J. Gill. (2022) A Critical Assessment of Current Grading Schemes for Diffuse Pleural Mesothelioma With a Proposal for a Novel Mesothelioma Weighted Grading Scheme (MWGS). American Journal of Surgical Pathology 46:6, pages 774-785.
Crossref
Crossref
Melih ŞİMŞEK, Ulaş IŞIK & Orkun GÜRBÜZ. (2022) Malign mezotelyomada kemoterapi uygulamalarıChemotherapy applications in malign mesothelioma. Ege Tıp Dergisi 61:1, pages 15-21.
Crossref
Crossref
David B. Chapel & Michelle S. Hirsch. (2022) SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia. American Journal of Surgical Pathology 46:2, pages 213-219.
Crossref
Crossref
Sara Ricciardi, Francesco Carleo, Massimo O. Jaus, Marco Di Martino, Luigi Carbone, Alberto Ricci & Giuseppe Cardillo. (2021) Malignant Pleural Mesothelioma Nodal Status: Where Are We at?. Journal of Clinical Medicine 10:21, pages 5177.
Crossref
Crossref
Wanyuan Cui & Sanjay Popat. (2021) Pleural mesothelioma (PM) – The status of systemic therapy. Cancer Treatment Reviews 100, pages 102265.
Crossref
Crossref
Sam M. JanesDoraid AlrifaiDean A. Fennell. (2021) Perspectives on the Treatment of Malignant Pleural Mesothelioma. New England Journal of Medicine 385:13, pages 1207-1218.
Crossref
Crossref
DeVon Hunter-Schlichting, Karl T. Kelsey, Ryan Demmer, Manish Patel, Raphael Bueno, Brock Christensen, Naomi Fujioka, Deepa Kolarseri & Heather H. Nelson. (2021) Cytomegalovirus infection in malignant pleural mesothelioma. PLOS ONE 16:8, pages e0254136.
Crossref
Crossref
Li Jiang, Hao Zheng, Qinying Lyu, Shotaro Hayashi, Kotaro Sato, Yoshitaka Sekido, Kae Nakamura, Hiromasa Tanaka, Kenji Ishikawa, Hiroaki Kajiyama, Masaaki Mizuno, Masaru Hori & Shinya Toyokuni. (2021) Lysosomal nitric oxide determines transition from autophagy to ferroptosis after exposure to plasma-activated Ringer's lactate. Redox Biology 43, pages 101989.
Crossref
Crossref
Navin K. Chintala, David Restle, Hue Quach, Jasmeen Saini, Rebecca Bellis, Michael Offin, Jason Beattie & Prasad S. Adusumilli. (2021) CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. Lung Cancer 157, pages 48-59.
Crossref
Crossref
Benjamin Wadowski, Raphael Bueno & Assunta De Rienzo. (2021) Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma. Frontiers in Oncology 11.
Crossref
Crossref
Wanyuan Cui & Sanjay Popat. (2021) Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma. Drugs 81:9, pages 971-984.
Crossref
Crossref
Andrea Billè, Lawrence Okiror, Leanne Harling, Fausto Pernazza, Alberto Muzio, Annalisa Roveta & Federica Grosso. (2020) Analysis of survival of patients with metastatic malignant pleural mesothelioma. Tumori Journal 107:2, pages 110-118.
Crossref
Crossref
Rajiv Shah, Laura V. Klotz, Inn Chung, Manuel Feißt, Marc A. Schneider, Johanna Riedel, Helge Bischoff, Martin E. Eichhorn & Michael Thomas. (2021) A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. Clinical Lung Cancer 22:2, pages 142-146.
Crossref
Crossref
Yin P. Hung & Lucian R. Chirieac. (2020) Pathology of Malignant Pleural Mesothelioma. Thoracic Surgery Clinics 30:4, pages 367-382.
Crossref
Crossref
Roshal Patel, Ethan B. Ludmir, Joseph A. Miccio, Hari Menon, Andrew R. Barsky, Shane M. Mesko, Manya Kodali, Tim Lautenschlaeger, Sebastian Adeberg, Charles B. SimoneIIII & Vivek Verma. (2020) Disease-Related Outcomes and Toxicities of Intensity Modulated Radiation Therapy After Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review. Practical Radiation Oncology 10:6, pages 423-433.
Crossref
Crossref
N. Vénissac, C. Cohen, D. Pop & J. Mouroux. (2020) Trattamento chirurgico del mesotelioma pleurico. EMC - Tecniche Chirurgiche Torace 24:1, pages 1-13.
Crossref
Crossref
Eric Rozitis, Ben Johnson, Yuen Yee Cheng & Kenneth Lee. (2020) The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review. Frontiers in Oncology 10.
Crossref
Crossref
Ece Cakiroglu & Serif Senturk. (2020) Genomics and Functional Genomics of Malignant Pleural Mesothelioma. International Journal of Molecular Sciences 21:17, pages 6342.
Crossref
Crossref
Andrew B. Thompson, Thomas J. Quinn, Zaid A. Siddiqui, Muayad F. Almahariq, Inga S. Grills & Craig W. Stevens. (2020) Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study. Lung Cancer 146, pages 120-126.
Crossref
Crossref
Isabelle Opitz, Arnaud Scherpereel, Thierry Berghmans, Ioannis Psallidas, Markus Glatzer, David Rigau, Philippe Astoul, Servet Bölükbas, Jeanette Boyd, Johan Coolen, Charlotte De Bondt, Dirk De Ruysscher, Valerie Durieux, Corinne Faivre-Finn, Dean A Fennell, Francoise Galateau-Salle, Laurent Greillier, Mir Ali Hoda, Walter Klepetko, Aude Lacourt, Phil McElnay, Nick A Maskell, Luciano Mutti, Jean-Claude Pairon, Paul Van Schil, Jan P van Meerbeeck, David Waller, Walter Weder, Paul Martin Putora & Giuseppe Cardillo. (2020) ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. European Journal of Cardio-Thoracic Surgery 58:1, pages 1-24.
Crossref
Crossref
Arnaud Scherpereel, Isabelle Opitz, Thierry Berghmans, Ioannis Psallidas, Markus Glatzer, David Rigau, Philippe Astoul, Servet Bölükbas, Jeanette Boyd, Johan Coolen, Charlotte De Bondt, Dirk De Ruysscher, Valerie Durieux, Corinne Faivre-Finn, Dean Fennell, Francoise Galateau-Salle, Laurent Greillier, Mir Ali Hoda, Walter Klepetko, Aude Lacourt, Phil McElnay, Nick A. Maskell, Luciano Mutti, Jean-Claude Pairon, Paul Van Schil, Jan P. van Meerbeeck, David Waller, Walter Weder, Giuseppe Cardillo & Paul Martin Putora. (2020) ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. European Respiratory Journal 55:6, pages 1900953.
Crossref
Crossref
Annalisa Trama, Claudia Proto, Diego Signorelli, Marina C. Garassino, Giuseppe Lo Russo, Monica Ganzinelli, Arsela Prelaj, Carolina Mensi, Manuela Gangemi, Valerio Gennaro, Elisabetta Chellini, Adele Caldarella, Italo F. Angelillo, Valeria Ascoli, Cristiana Pascucci, Giovanna Tagliabue, Rosanna Cusimano, Francesca Bella, Fabio Falcini, Enzo Merler, Giuseppe Masanotti, Antonio Ziino, Maria Michiara, Gemma Gola, Cinzia Storchi, Lucia Mangone, Maria F. Vitale, Claudia Cirilli, Rosario Tumino, Tiziana Scuderi, Anna C. Fanetti, Silvano Piffer, Marcello Tiseo, Gemma Gatta & Laura Botta. (2020) Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population‐based nationwide study. Thoracic Cancer 11:6, pages 1661-1669.
Crossref
Crossref
Yu Zhi Zhang, Cecilia Brambilla, Philip L. Molyneaux, Alexandra Rice, Jan L. Robertus, Simon Jordan, Eric Lim, Loic Lang-Lazdunski, Sofina Begum, Michael Dusmet, Vladimir Anikin, Emma Beddow, Jonathan Finch, Nizar Asadi, Sanjay Popat, William O.C. Cookson, Miriam F. Moffatt & Andrew G. Nicholson. (2020) Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting. American Journal of Surgical Pathology 44:3, pages 347-356.
Crossref
Crossref
David B. Chapel, Jefree J. Schulte, Kyra Berg, Andrew Churg, Sanja Dacic, Carrie Fitzpatrick, Francoise Galateau-Salle, Kenzo Hiroshima, Thomas Krausz, Nolwenn Le Stang, Stephanie McGregor, Kazuki Nabeshima & Aliya N. Husain. (2020) MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Modern Pathology 33:2, pages 245-254.
Crossref
Crossref
Kristin J. Cummings, Michael J. Becich, David J. Blackley, Dennis Deapen, Robert Harrison, Raffit Hassan, S. Jane Henley, Mary Hesdorffer, D. Kevin Horton, Jacek M. Mazurek, Harvey I. Pass, Emanuela Taioli, Xiao‐Cheng Wu, Marjorie G. Zauderer & David N. Weissman. (2019) Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry. American Journal of Industrial Medicine 63:2, pages 105-114.
Crossref
Crossref
D.V. Sidorov, N.A. Grishin, M.V. Lozhkin, A.A. Troitsky, I.V. Stepanyuk, S.A. Bykasov & R.I. Moshurov. (2020) Tumors of peritoneum. Treatment algorithms. Onkologiya. Zhurnal imeni P.A.Gertsena 9:4, pages 60.
Crossref
Crossref
Allison S. Letica-Kriegel, Joshua C. Leinwand, Joshua R. Sonett, Lyall A. Gorenstein, Robert N. Taub, John A. Chabot & Michael D. Kluger. (2019) 50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience. Annals of Surgical Oncology 27:1, pages 205-213.
Crossref
Crossref
Ayşe Gül ERGÖNÜL, Tevfik İlker AKÇAM, Ali ÖZDİL, Kutsal TURHAN, Alpaslan ÇAKAN, Deniz NART, Serdar ÖZKÖK, Erdem GÖKER, Ayşe CANER, Gürsel ÇOK & Ufuk ÇAĞIRICI. (2019) Ege Üniversitesi Hastanesi malign plevral mezotelyoma hastalarının epidemiyolojik ve genel sağ kalım özellikleriEpidemiological and general survival characteristics of malign plevral mesothelioma patients in Ege University Hospital. Ege Tıp Dergisi, pages 140-144.
Crossref
Crossref
Yusuke Nagata, Ryoichi Sawada, Atsuo Takashima, Hirokazu Shoji, Yoshitaka Honma, Satoru Iwasa, Katsushi Amano, Ken Kato, Tetsuya Hamaguchi, Yasuhiro Shimada, Masayuki Saruta & Narikazu Boku. (2019) Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma. Japanese Journal of Clinical Oncology 49:11, pages 1004-1008.
Crossref
Crossref
Jan H. Rüschoff, Elise Gradhand, Abdullah Kahraman, Helen Rees, Jane L. Ferguson, Alessandra Curioni-Fontecedro, Martin Zoche, Holger Moch & Bart Vrugt. (2019)
STRN
-ALK
Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
. JCO Precision Oncology:3, pages 1-6.
Crossref
Crossref
Anne Warby, Haryana M. Dhillon, Steven Kao & Janette L. Vardy. (2019) Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma. Supportive Care in Cancer 27:9, pages 3509-3519.
Crossref
Crossref
Evdoxia Gogou, Chrissi Hatzoglou, Sotirios G. Zarogiannis, Foteini Malli, Rajesh M. Jagirdar & Konstantinos I. Gourgoulianis. (2019) Mesothelioma Mortality Rates in Greece for the Period 2005–2015 Is Increased Compared to Previous Decades. Medicina 55:8, pages 419.
Crossref
Crossref
Darragh Halpenny, Micheal Raj, Andreas Rimner, Junting Zheng, Marinela Capanu & Michelle S. Ginsberg. (2019) Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy. European Radiology 29:7, pages 3696-3704.
Crossref
Crossref
David B. Chapel, Rachel Stewart, Larissa V. Furtado, Aliya N. Husain, Thomas Krausz & Georgios Deftereos. (2019) Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Human Pathology 87, pages 11-17.
Crossref
Crossref
Shinya Toyokuni. (2019) Iron addiction with ferroptosis-resistance in asbestos-induced mesothelial carcinogenesis: Toward the era of mesothelioma prevention. Free Radical Biology and Medicine 133, pages 206-215.
Crossref
Crossref
Eric Borrelli, Zachary Babcock & Stephen Kogut. (2019) Costs of medical care for mesothelioma. Rare Tumors 11, pages 203636131986349.
Crossref
Crossref
Gwendolyn Cramer, Michael Shin, Sarah Hagan, Sharyn I Katz, Charles B. SimoneIIII, Theresa M. Busch & Keith A. Cengel. (2019) Modeling Epidermal Growth Factor Inhibitor-mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture. Photochemistry and Photobiology 95:1, pages 397-405.
Crossref
Crossref
Bryan Q. Spring & David Kessel. (2019) 3D Culture Models of Malignant Mesothelioma Reveal a Powerful Interplay Between Photodynamic Therapy and Kinase Suppression Offering Hope to Reduce Tumor Recurrence. Photochemistry and Photobiology 95:1, pages 462-463.
Crossref
Crossref
Richard D. Hemingway. 2019. Caring for Patients with Mesothelioma: Principles and Guidelines. Caring for Patients with Mesothelioma: Principles and Guidelines
99
119
.
Nguyen Son Lam, Nguyen Van Tho, Tran Dinh Thanh & Yasutaka Nakano. 2019. Microbiome and Cancer. Microbiome and Cancer
167
183
.
Rebecca M. Schwartz, Wil Lieberman-Cribbin, Andrea Wolf, Raja M. Flores & Emanuela Taioli. (2018) Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma. BMC Cancer 18:1.
Crossref
Crossref
Fausto Petrelli, Raffaele Ardito, Barbara Conti, Andrea Coinu, Mary Cabiddu, Mara Ghilardi, Karen Borgonovo, Sandro Barni & Antonio Ghidini. (2018) A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. Respiratory Medicine 141, pages 72-80.
Crossref
Crossref
Luka Brcic, Gregor Vlacic, Franz Quehenberger & Izidor Kern. (2018) Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping. Archives of Pathology & Laboratory Medicine 142:6, pages 747-752.
Crossref
Crossref
Monica S Chatwal & Tawee Tanvetyanon. (2018) Malignant mesothelioma clinical trial combines immunotherapy drugs. Immunotherapy 10:5, pages 341-344.
Crossref
Crossref
Sahar A. Saddoughi, Zaid M. Abdelsattar & Shanda H. Blackmon. (2018) National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study. The Annals of Thoracic Surgery 105:2, pages 432-437.
Crossref
Crossref
Ori Wald & David J. Sugarbaker. (2018) New Concepts in the Treatment of Malignant Pleural Mesothelioma. Annual Review of Medicine 69:1, pages 365-377.
Crossref
Crossref
David B. Chapel, Aliya N. Husain, Thomas Krausz & Stephanie M. McGregor. (2017) PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. American Journal of Surgical Pathology 41:12, pages 1675-1682.
Crossref
Crossref
Sara Tannenbaum, Pamela R. Soulos, Jeph Herrin, Sarah Mougalian, Jessica B. Long, Rong Wang, Xiaomei Ma, Cary P. Gross & Xiao Xu. (2017) Regional Medicare Expenditures and Survival Among Older Women With Localized Breast Cancer. Medical Care 55:12, pages 1030-1038.
Crossref
Crossref
Erika G. Odisio, Edith M. Marom, Girish S. Shroff, Carol C. Wu, Ana Paula A. Benveniste, Mylene T. Truong & Marcelo F. Benveniste. (2017) Malignant Pleural Mesothelioma: Diagnosis, Staging, Pitfalls and Follow-up. Seminars in Ultrasound, CT and MRI 38:6, pages 559-570.
Crossref
Crossref
Vivek Verma, Christopher A. Ahern, Christopher G. Berlind, William D. Lindsay, Sonam Sharma, Jacob Shabason, Melissa J. Culligan, Surbhi Grover, Joseph S. Friedberg & Charles B. SimoneIIII. (2017) National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma. Journal of Thoracic Oncology 12:11, pages 1704-1714.
Crossref
Crossref
Aline N. Zouk & Hitesh Batra. (2017) Malignant Pleural Mesothelioma: Spotlight on Recent Advances in Diagnosis and Treatment. EMJ Oncology, pages 103-111.
Crossref
Crossref
Lindsey Enewold, Elad Sharon & Anish Thomas. (2017) Patterns of care and survival among patients with malignant mesothelioma in the United States. Lung Cancer 112, pages 102-108.
Crossref
Crossref
Chao He, Bo Wang, Chun Wan, Ting Yang & Yongchun Shen. (2017) Diagnostic value of D2-40 immunostaining for malignant mesothelioma: a meta-analysis. Oncotarget 8:38, pages 64407-64416.
Crossref
Crossref
Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim Aerts, Susana Cedres Perez, Alessandra Bearz, Kristiaan Nackaerts, Dean A Fennell, Dariusz Kowalski, Anne S Tsao, Paul Taylor, Federica Grosso, Scott J Antonia, Anna K Nowak, Maria Taboada, Martina Puglisi, Paul K Stockman & Hedy L Kindler. (2017) Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet Oncology 18:9, pages 1261-1273.
Crossref
Crossref
Katja Goričar, Viljem Kovač & Vita Dolžan. (2017) Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. Scientific Reports 7:1.
Crossref
Crossref
N. A. Grishin, D. V. Sidorov, L. A. Vashakmadze, V. V. Sokolov, E. V. Filonenko, N. A. Rubtsova, I. V. Kolobaev & E. A. Suleimanov. (2017) A case of successful combined treatment in female patient with malignant epithelioid mesothelioma of the peritoneum. Onkologiya. Zhurnal imeni P.A.Gertsena 6:6, pages 52.
Crossref
Crossref